trending Market Intelligence /marketintelligence/en/news-insights/trending/Nsw3t541ANkC8ht-QMCX0Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

XBiotech's bowel cancer treatment passes phase 3 trial

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


XBiotech's bowel cancer treatment passes phase 3 trial

XBiotech Inc. reported positive results from a phase 3 study evaluating its Hutruo antibody therapy as a potential treatment of advanced colorectal cancer, also known as bowel cancer and colon cancer.

According to the results, 40% of the patients who received the treatment achieved the main goal of reduced disease progression, as measured by the combination of patient-reported symptoms and radiography. This was nearly double compared to patients who received placebo.

Further, patients who achieved the primary endpoint demonstrated substantially improved survival outcomes, with a median survival of 11.7 months compared to the 5.7 months for those who did not.